REMAP ECMO is a registry based platform in which multiple response adaptive randomized clinical trials (trial domains) will be embedded. These trial domains will, in a perpetual way, study the effects of a range of patient management strategies which aim to improve VA ECMO weaning success. A first trial domain will address the effects of left ventricular (LV) unloading through intra-aortic balloon pumping on weaning succes in VA ECMO supported patients.
ExtraCorporeal Membrane Oxygenation (ECMO) is increasingly used but remains associated with high weaning failure- and mortality- rates. This seems in part attributable to a knowledge gap on how to properly manage ECMO and its related therapies as current knowledge and treatment protocols are based on observational studies and expert opinions. The "Randomized Embedded Multifactorial Adaptive Platform in ECMO" (REMAP ECMO) study was developed to study, in an efficient and randomized way, different ECMO related patient management issues and will consist of two parts: 1. A patient registry that will serve for quality monitoring and observational studies of ECMO patients being treated in participating centers. 2. Embedded within the registry, multiple response adaptive randomized clinical trials (trial domains) which aim to evaluate the effectiveness of a range of therapeutic interventions on ECMO weaning success. These interventions all have in common that they are all already used in ECMO care but their use depends on center and/or doctors preferences as no high quality (randomized) evidence guiding their indication, timing and management exists. * LV unloading trial A first trial domain to be initiated within the REMAP ECMO platform will address the effects of left ventricular (LV) unloading, through application of an intra-aortic balloon pump (IABP), on weaning success in the setting of venoarterial (VA) ECMO. The rationale of this trial domain is based on the increase in LV loading conditions, as induced by VA ECMO, which could lead to pulmonary edema, intracardiac thrombosis and even death. These serious sequelae could possibly be prevented by adding IABP as adjunct to VA ECMO therapy. * Physiological substudy on IABP as adjunct to V-A ECMO A nested physiological observational substudy within the ongoing REMAP ECMO RCT, using the trial arms where patients are randomized between receiving V-A ECMO with or without IABP in the Erasmus Medical Center Rotterdam. The substudy aims to evaluate the physiological effects of IABP in conjunction with V-A ECMO on respiratory and hemodynamic parameters. The substudy consists of two parts: 1. Microcirculation and Macrocirculation: This part investigates the impact of IABP on both microcirculation and macrocirculation in the setting of V-A ECMO. 2. PEEP as an Unloading Modality: This part examines the effect of Positive End-Expiratory Pressure (PEEP) as an unloading modality during a decremental PEEP trial in patients receiving V-A ECMO, either with or without IABP. Endpoints in both substudies that can be assessed blindly will be evaluated by an assessor who is blinded to the assigned treatment arm and the objectives of the substudy
An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
AZ Sint-Jan Brugge
Bruges, Belgium
RECRUITINGZOL Genk
Genk, Belgium
ECMO weaning success
Proportion of patients successfully weaned from VA ECMO at 30 days being defined by; a) being alive, b) without ECMO, IABP or Impella support, and c) not having received a heart transplantation or left ventricular assist device (LVAD).
Time frame: 30 days
Physiological substudy: End diastolic volume
End diastolic volume as assessed by echocardiography
Time frame: within 24 hours after ECMO initiation
Treatment failure
The proportion of patients in whom LV unloading therapy was escalated. Escalation is defined by the insertion of an IABP (only in the VA ECMO alone arm), or Impella or left vent (IABP unloading arm or VA ECMO alone arm).
Time frame: During ECMO support
30 day, 90 day and 1 year mortality
Mortality rate at 30 days, 90 days and 1 year after ECMO initiation
Time frame: 30 days, 90 days and 1 year after ECMO initiation
ECMO support duration
The duration of ECMO support in days
Time frame: Until 30 days after ECMO initiation
Major bleeding events
The occurrence of major bleeding events (fatal, in a critical area (intracranial, intraspinal, or intraocular), requiring intervention (coiling or surgery) and/or transfusion of ≥3 packed cells) until 30 days after VA ECMO initiation.
Time frame: Until 30 days after ECMO initiation
Unplanned surgical or catheter based intervention of the leg(s)
Unplanned surgical or catheter based intervention of the leg(s) in which ECMO and/or IABP or Impella was inserted until 30 days after ECMO initiation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
430
UZ Gent
Ghent, Belgium
RECRUITINGAmphia hospital
Breda, North Brabant, Netherlands
NOT_YET_RECRUITINGCatharina hospital
Eindhoven, North Brabant, Netherlands
NOT_YET_RECRUITINGAmsterdam University Medical Center
Amsterdam, North Holland, Netherlands
NOT_YET_RECRUITINGLeiden University Medical Center
Leiden, South Holland, Netherlands
NOT_YET_RECRUITINGErasmus Medical Center
Rotterdam, South Holland, Netherlands
RECRUITINGHaga ziekenhuis
The Hague, South Holland, Netherlands
NOT_YET_RECRUITINGAntonius hospital
Nieuwegein, Utrecht, Netherlands
NOT_YET_RECRUITING...and 4 more locations
Time frame: Until 30 days after ECMO initiation
Time to lactate normalization
Time to lactate normalization (\<2 mmol/L).
Time frame: Until 30 days after ECMO initiation
Time to first negative net fluid balance
Time to first negative net fluid balance (calculated per 24 hours).
Time frame: Until 30 days after ECMO initiation
The occurrence of continuous venovenous hemofiltration initiation during ECMO support
The occurrence of continuous venovenous hemofiltration (dialysis) (CVVH(D)) initiation during ECMO support.
Time frame: Until 30 days after ECMO initiation
Course in PF ratio
Course in PaO2/FiO2 (PF) ratio (PaO2 divided by FiO2 provided)
Time frame: Until 30 days after ECMO initiation.
Duration of mechanical ventilation.
Duration of mechanical ventilation. Patients on mechanical ventilation via tracheostomy need to be 24 hours free of mechanical ventilation.
Time frame: Until 30 days after ECMO initiation.
Left ventricular ejection fraction 30 days after ECMO initiation.
Left ventricular ejection fraction 30 days after ECMO initiation.
Time frame: At 30 days after ECMO initiation.
Time course in vasoactive inotropic score (VIS) during ECMO support
Time course in vasoactive inotropic score (VIS) during ECMO support
Time frame: Until 30 days after ECMO initiation.
Time course in NT-pro BNP during ECMO support.
Time course in NT-pro BNP during ECMO support.
Time frame: Until 30 days after ECMO initiation.
Quality of life at 1 year
Quality of life on basis of EQ5D questionnaires
Time frame: 1 year after ECMO initiation
Total health care costs
Total healthcare costs in euros are determined by using the International Medical Consumption Questionnaire (iMCQ) and the calculated costs after 6 and 12 months of follow up
Time frame: 6 and 12 months after ECMO initiation
Hospital readmission rate
The number of hospital readmissions based on the information provided in the international Medical Consumption Questionnaire (iMCQ)
Time frame: 1 year
Physiological substudy: Heart rate
The average heart rate measured during 5 minutes
Time frame: 24 and 48 hours after ECMO initiation
Physiological substudy: pulmonary artery catheter parameters
pulmonary artery catheter parameters: pulmonary capillary wedge pressure, cardiac output, central venous pressure
Time frame: 24 and 48 hours after ECMO initiation
Physiological substudy: Echocardiography
Echocardiography: LV ejection fraction, TAPSE, VTI LVOT
Time frame: 24 and 48 hours after ECMO initiation
Physiological substudy: microcirculation measurements
Microcirculation measurements: Perfused vessel density (PVD \[mm/mm2\], Total vessel density (TVD \[mm/mm2\]
Time frame: 24 and 48 hours after ECMO initiation
Physiological substudy: respiratory parameters
Respiratory: FiO2, PEEP, Respiratory System Compliance (CRS) as the ratio between Vt/Dp.
Time frame: 24 and 48 hours after ECMO initiation
Physiological substudy: delta NT-pro BNP
delta NT-pro BNP
Time frame: 24 and 48 hours after ECMO initiation